Target intelligence / Profile preview

Potassium channel subfamily K member 17 (KCNK17)

Target
KCNK17
Molecular classification
Ion channel, Two-pore domain potassium (K2P) channel
01

Overview

Potassium channel subfamily K member 17 (KCNK17) encodes a two-pore domain potassium (K2P) channel, also known as TASK-4 or TALK-2, that conducts outward rectifying potassium currents and helps establish the resting membrane potential in excitable cells. It is activated at alkaline pH values, displaying a sensitivity unique among K2P channels. KCNK17 is highly expressed in tissues such as the heart, pancreas, liver, and brain, where it regulates electrical excitability. Gain-of-function mutations are implicated in cardiac conduction disorders and idiopathic ventricular fibrillation, while genetic variants have been associated with increased risk of ischemic stroke and cerebral hemorrhage. It is considered a potential therapeutic target for arrhythmias and stroke due to its critical role in cardiac and cerebrovascular excitability.

Other names
K2P17.1TALK-2TALK2TASK-4TASK42P domain potassium channel Talk-2Acid-sensitive potassium channel protein TASK-4TWIK-related acid-sensitive K(+) channel 4TWIK-related alkaline pH-activated K(+) channel 2TWIK-related acid-sensitive K+ 4potassium channel, two pore domain subfamily K, member 17
02

Mechanism of action

Modulation (typically inhibition or potentiation) of channel activity affects membrane potential and excitability of cells, particularly in cardiac and neural tissues. Alkaline pH activation is unique among K2P channels.

03

Biological functions

Potassium ion transmembrane transportRegulation of resting membrane potentialModulation of cellular excitabilityContribution to cardiac action potential (cardiac conduction system)Regulation of pancreatic β-cell function
04

Disease associations

Cardiac conduction disorders (including progressive cardiac conduction disorder, arrhythmia, idiopathic ventricular fibrillation)Ischemic strokeCerebral hemorrhageBirk-Barel syndromeAdrenal cortical adenocarcinoma
05

Safety considerations

Potential for arrhythmia or cardiac conduction abnormalities if modulated incorrectly (gain-of-function mutations cause cardiac conduction disorders and ventricular fibrillation)
06

Interacting drugs

No FDA-approved drugs are specifically cited; literature references suggest pharmacological modulators exist but are not clinically utilized for this specific channel.
07

Biomarkers

KCNK17 gene variant rs10947803 A allele (linked to ischemic stroke risk and altered gene expression)

Beyond the preview

Go deeper on Potassium channel subfamily K member 17 (KCNK17).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium channel subfamily K member 17 (KCNK17).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call